<code id='F907DC7963'></code><style id='F907DC7963'></style>
    • <acronym id='F907DC7963'></acronym>
      <center id='F907DC7963'><center id='F907DC7963'><tfoot id='F907DC7963'></tfoot></center><abbr id='F907DC7963'><dir id='F907DC7963'><tfoot id='F907DC7963'></tfoot><noframes id='F907DC7963'>

    • <optgroup id='F907DC7963'><strike id='F907DC7963'><sup id='F907DC7963'></sup></strike><code id='F907DC7963'></code></optgroup>
        1. <b id='F907DC7963'><label id='F907DC7963'><select id='F907DC7963'><dt id='F907DC7963'><span id='F907DC7963'></span></dt></select></label></b><u id='F907DC7963'></u>
          <i id='F907DC7963'><strike id='F907DC7963'><tt id='F907DC7963'><pre id='F907DC7963'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:leisure time    Page View:457
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Cue Health, Covid
          Cue Health, Covid

          AdobeInanabruptchangeofcoursefromplansearlierinthemonth,at-hometestmakerCueHealthislayingoffallofits

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Making the case for fair compensation in clinical trials

          AdobeI’vebeenonthreesidesofthehealthcareequation:I’vebeatenstage4colorectalcancer,I’mthemotherofason